• MicroRNA21-3p and microRNA885-5p as markers of viral hepatitis in infants
To content

MicroRNA21-3p and microRNA885-5p as markers of viral hepatitis in infants

SOVREMENNAYA PEDIATRIYA. 2015.1(65):96-101; doi 10.15574/SP.2015.65.96

 

MicroRNA21-3p and microRNA885-5p as markers of viral hepatitis in infants

 

Shadrin A. G., Chernega N. F., Guryanova V. L., Dosenko V. E.

Institute of PAG NAMS of Ukraine, Kiev

A.A. Bogomolets Institute of Physiology NAMS of Ukraine, Kiev

 

Objective. To study the levels of serum miRNAs in infants with viral hepatitis.

 

Patients and methods. A total of 22 infants with hepatitis — 17 of cytomegalovirus etiology and 5 HBV-etiology were under observation. Complex examinations included an analysis of anamnestic data and clinical and paraclinical investigations. Levels of miRNA-21–3p and miRNA-885—5p in the blood serum of children with hepatitis and healthy children were determined by the use of TaqMan method. The obtained data were analyzed with the use of «7500 Fast Real-time PCR» software and demonstrated in the graphic form.

 

Results. It is revealed that the levels of miRNA-21—3p and miRNA-885—5p in children with hepatitis are higher in comparison with healthy (p<0.05). At CMV-hepatitis miRNA-21—3p is 2.2728 CU against 0.6516 CU in healthy; miRNA-885—5p — 1.7244 CU against 0.1801 CU. At HBV, hepatitis-miRNA-21-3p — 38.9124 CU against 0.6516 CU, respectively; miRNA-885-5p — 1.7244 CU against 0.1801 against CU in healthy. The level of miRNA-21-3p significantly higher in the group of children with hepatitis of HBV-etiology in comparison with children with hepatitis of CMV-etiology (p<0.05).

 

Conclusions. The increase of the content of miRNA-21-3p during the viral liver lesions denote the decisive role of miRNA-21-3p as a regulator of the immune response and can be used as a diagnostic biomarker. The highest level of miRNA-21-3p in children with HBV-hepatitis pointed at a deeper involvement of the immune mechanisms that determine the further course of the disease. These studies confirm the need for inclusion of hepatoprotective and immunocorrective therapy during the viral hepatitis, according to the degree of inflammatory activity.

 

Key words: microRNA, cytomegalovirus, hepatitis B virus, hepatitis, infants

 

REFERENCES

1. Учайкин ВФ, Смирнов АВ, Чуелов СБ, Россина АЛ. 2012. Герпесвирусные гепатиты у детей. Педиатрия. 91;3: 136—142.

2. Крамарев СА. 2013. Вирусные гепатиты у детей. Здоровье Украины. http://www.health-ua.org/archives/immuno/4.html.

3. Cовременные критерии диагностики и подходы к лечению хронического гепатита у детей. Метод реком. К. 2010: 41.

4. Хаертынов ХС. Анохин ВА, Низамова ЭР. 2012. Клинико-эпидемиологические особенности неонатальных гепатитов. Казанский мед журн. XCII;6: 921—926.

5. Yamada H et al. 2013. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and nonalcoholic fatty liver. Clin Chim Acta. 424: 99—103.

6. Novellino L, Rossi RL, Bonino F et al. 2012. Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs. PLOS ONE. 7. e31952.10.1371/journal.pone.0031952. PubMed: 22470417.

7. Jian Xu1, Chen Wu1, Xu Che et al. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Molecular Carcinogenesis. 50(2): 136—142.

8. Wang K, Zhang S, Marzolf B et al. 2009. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA. 106: 4402-4407.10.1073/pnas.0813371106.

9. Enache LS, Enache EL, Ramiere C et al. 2014. Circulation RNA Molecules as Biomarcers in Liver Diseases. International Journal of Molecular Sciences. 15(10): 17644—17666. http://dx.doi.org/10.3390/ijms151017644; PMid:25272224 PMCid:PMC4227182

10. Murakami Y, Toyoda H, Tanahashi T et al. 2012. Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease. PLoS One. 7(10): e48366. http://dx.doi.org/10.1371/journal.pone.0048366; Epub 2012 Oct 31.

11. Marquez RT, Bandyopadhyay S, Wendlandt EB et al. 2010. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest. 90: 1727—1736.

12. Winther TN, Bang-Berthelsen CH, Heiberg IL et al. 2013. Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B. PLoS One. 8(3): e58236.

13. Valadi H, Ekstrom K, Bossios A et al. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Товарbiol. 9: 654—659. 10.1038/ncb1596. PubMed: 17486113.

14. Castro RE, Ferreira DM, Zhang X et al. 2010. Identification of microRNAs during rat liver regeneration after partial hepatectomy and modulation by ursodeoxycholic acid. Am J Physiol Gastrointest Liver Physiol. 299(4): 887—897.

15. Pedersen IM, Cheng G, Wieland S et al. 2007. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 449: 919—922.

16. Liu WH, Yeh SH, Chen PJ. 2011. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta. 1809: 678—685.

17. Marcellin P, Levy S, Erlinger S. 1997. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology. 26: 133—136. S.10.1002/hep.510260723.

18. Wei J, Feng L, Li Z et al. 2013. MicroRNA-21 activates hepatic stellate cells via PTEN. Akt signaling. Biomed Pharmacother. 67: 387—392. http://dx.doi.org/10.1016/j.biopha.2013.03.014. PubMed: 23643356.

19. Marquez RT, Wendlandt E, Galle CS et al. 2010. MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-kappaB signaling. Am J Physiol Gastrointest Liver Physiol. 298: 535—541.

20. Zhao J, Tang N, Wu K et al. 2014. MiR-21 Simultaneously Regulates ERK1 Signaling in HSC Activation and Hepatocyte EMT in Hepatic Fibrosis. PLoS One. 9(10): e108005. Published online 2014 October 10. http://dx.doi.org/10.1371/journal.pone.0108005.

21. Zhang Y, Jia Y, Zheng R et al. 2010. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem. 56: 1830—1838.

22. Kosaka N, Iguchi H, Yoshioka Y et al. 2010. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Товарbiol Chem. 285: 17442—17452. 10.1074/-jbc.M110.107821 PubMed: 20353945. PMC free article.

23. Junhao Gui, Yaping Tian, Xinyu Wen et al. 2011. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond). 120 (Pt 5): 183—193. Prepublished online 2010 September 3. Published online 2010 November 19. http://dx.doi.org/10.1042/CS20100297.

24. Li L-M, Hu Z-B, Zhou Z-X et al. 2010. Serum microRNA profiles serve as novel biomarkers of HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 70(23): 9798—807. DOI: 10.1158/0008—5472.CAN-10-1001. PMID:21098710.

25. Waidmann O, Bihrer V, Pleli T et al. 2012. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat. 19(2): 58—65. http://dx.doi.org/10.1111/j.1365-2893.2011.01536.x; PMid:22239527

26. Bihrer V, Waidmann O, Friedrich-Rust M et al. 2011. Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma. PLoS One. 6(10): e26971. Published online 2011 October 31. http://dx.doi.org/10.1371/journal.pone.0026971.

27. Liu X, Wang T, Wakita T, Yang W. 2010. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology. 398: 57—67.

28. Zhang B, Wang Q, Pan X. 2007. MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol. 210: 279—289.